PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS

被引：1
|
作者：
Pradelli, L. [1 ]
Calandriello, M. [2 ]
Di Virgilio, R. [3 ]
Bellone, M. [1 ]
Tubaro, M. [4 ]
机构：
[1] AdRes HE&OR, Turin, Italy
[2] Bristol Myers Squibb Srl, HE OR Unit, Rome, Italy
[3] Pfizer Pharmaceut Inc, Rome, Italy
[4] San Filippo Neri Hosp, Rome, Italy
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1427
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV83
引用
收藏
页码：A486 / A487
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Chan, E.
    Li, X.
    Lau, C.
    Anand, S.
    VALUE IN HEALTH, 2016, 19 (07) : A866 - A867
  • [42] TRENDS AND PREDICTORS OF NOAC VERSUS WARFARIN USE FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Brownell, Kenneth B.
    Sezer, Ahmet
    Jain, Sandeep
    Thoma, Floyd
    Kancharla, Krishna
    Bhonsale, Aditya
    Saba, Samir
    Mulukutla, Suresh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 518 - 518
  • [43] Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation
    Sascha Meyer dos Santos
    Sebastian Harder
    Drug Safety, 2014, 37 : 295 - 307
  • [44] Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
    Sulaiman, Khalid Al
    Aljuhani, Ohoud
    Alkofide, Hadeel
    Aljohani, Manal A.
    Badreldin, Hisham A.
    Al Harbi, Mahasen
    Aquil, Ghalia
    Alhajaji, Raghad
    Alqahtani, Rahaf A.
    Babonji, Alaa
    Altuwayr, Maha
    Alshehri, Asma A.
    Alfaifi, Mashael
    Alharthi, Abdullah F.
    Alzahrani, Mohammed
    Al Sulaiman, Tareq
    Alqahtani, Nasser
    Alshahrani, Walaa A.
    Al Katheri, Abdulmalik
    Albekairy, Abdulkareem M.
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [45] Efficacy and safety of apixaban vs edoxaban for stroke prevention in non-valvular atrial fibrillation: an indirect treatment analysis
    Lip, G. Y. H.
    Mitchell, S. A.
    Liu, X. C.
    Phatak, H.
    Batson, S.
    EUROPEAN HEART JOURNAL, 2014, 35 : 895 - 896
  • [46] ADHERENCE TO RIVAROXABAN, DABIGATRAN, AND APIXABAN FOR STROKE PREVENTION IN INCIDENT, TREATMENT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION
    Brown, J.
    Shewale, A. R.
    Talbert, J.
    VALUE IN HEALTH, 2016, 19 (07) : A638 - A638
  • [47] Pharmacoeconomic evaluation of dabigatran vs warfarin in cardiovascular events prevention in patients with non-valvular atrial fibrillation
    Belousov, Yu. B.
    Mareev, V. Yu.
    Yavelov, I. S.
    Belousov, D. Yu.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2012, 8 (01) : 37 - 44
  • [48] Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran
    Tajik, Amirmohammad
    Abbasi, Azam
    Goudarzi, Zahra
    Izadi-Moud, Azadeh
    Varmaghani, Mehdi
    CLINICAL CARDIOLOGY, 2024, 47 (06)
  • [49] Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
    Halperin, Jonathan L.
    Dorian, Paul
    CURRENT CARDIOLOGY REVIEWS, 2014, 10 (04) : 297 - 302
  • [50] Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?
    Wong, C. W.
    HONG KONG MEDICAL JOURNAL, 2016, 22 (06) : 608 - 615
12345